Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)-Reference-Cited by-同舟云学术

Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)

Published:2021-09-16 Issue: Volume:2021 Page:1-8
ISSN:1875-8630
Container-title:Disease Markers
language:en
Short-container-title:Disease Markers

Author:

Zhang Wenqi¹^ORCID,Fan Yanfeng²^ORCID,Li Meng³^ORCID,Yang Linqi³^ORCID,Zhang Zhenya⁴^ORCID,Liu Lihong¹⁵^ORCID

Affiliation:

1. Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei Province, China

2. Department of Chemistry, Temple University, Philadelphia, Pennsylvania 19087, USA

3. School of Basic Medical Sciences, Hebei University of Chinese Medicine, Shijiazhuang, 050200 Hebei Province, China

4. Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei Province, China

5. Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang 050011, China

Abstract

At present, the use of the common chemotherapy regimen CHOP/R-CHOP for diffuse large B-cell lymphoma (DLBCL) has some shortcomings, especially for relapsed and refractory DLBCL. CD47 is now considered as a prominent target in cancer therapies, and CD47 blockade mainly inhibits the CD47-SIRPα axis to prevent tumor immune escape. Here, we evaluated the effects of the latest CD47 antibodies reported and the correlations of closely related genes with CD47 in this disease. In the future, therapeutic strategies for DLBCL will focus on multitarget antibody combined treatment and multigene joint attacks.

Funder

Construction of International Platform for Clinical Evaluation of Hematological Tumor and Major Solid Tumor Drugs

Publisher

Hindawi Limited

Subject

Biochemistry, medical,Clinical Biochemistry,Genetics,Molecular Biology,General Medicine

Link

http://downloads.hindawi.com/journals/dm/2021/4894022.pdf

Reference50 articles.

1. CD47: role in the immune system and application to cancer therapy

2. Role of CD47 as a Marker of Self on Red Blood Cells

3. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma;M. P. Chao;Cell,2010